Intesticortproct (Budesonide)

Budesonide is a glucocorticoid receptor agonist. After binding to intracellular receptors, it modulates gene transcription, suppressing pro‑inflammatory cytokines, inhibiting leukocyte migration, and stabilising cell membranes. This results in a potent anti‑inflammatory effect at the site of application.

The specific dose and treatment duration are determined by the prescribing clinician based on disease severity, patient response, and safety considerations. Healthcare professionals tailor the regimen to each individual, and patients should follow the prescriber’s instructions precisely.

Safety data for budesonide rectal use in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Patients should discuss their situation with a qualified healthcare provider before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Intesticortproct delivers budesonide, a high‑potency corticosteroid with strong local anti‑inflammatory activity and minimal systemic absorption. Compared with mesalamine enemas, budesonide often provides faster symptom relief but may carry a higher risk of corticosteroid‑related side effects. Choice of therapy depends on disease severity, patient tolerance, and physician preference.

Store the product at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures. Do not refrigerate or freeze the product, and keep it out of reach of children.

Intesticortproct is administered rectally. The prescribed dose is inserted into the rectum using the supplied applicator or a clean fingertip, following the instructions provided by the healthcare professional. Patients should remain lying down for a few minutes after insertion to ensure optimal absorption.

Serious risks include adrenal suppression with prolonged use, severe infections due to immunosuppression, allergic reactions such as rash or anaphylaxis, and rare events like colonic perforation or significant gastrointestinal bleeding. Patients should seek immediate medical attention if they experience signs of infection, severe abdominal pain, or allergic symptoms.

Intesticortproct is contraindicated in individuals with known hypersensitivity to budesonide or any excipients, those with active systemic infections, and patients with severe uncontrolled diabetes or uncontrolled hypertension where systemic corticosteroid effects could be harmful. Clinicians should evaluate each patient’s medical history before prescribing.